SCHEMBL11943328

SCHEMBL11943328

O=c1c(OCc2ccccc2)c(N2CCN(Cc3ccoc3)CC2)cnn1-c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 1/20 0.44
▸ ALDH1A1 P00352 4/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ POLB P06746 2/20 0.43
▸ HPGD P15428 1/20 0.43
▸ LMNA P02545 3/20 0.42
▸ MAPT P10636 3/20 0.42
▸ NPC1 O15118 4/20 0.41
▸ RAB9A P51151 4/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ SRPK1 Q96SB4 1/20 0.39
▸ DCTPP1 Q9H773 2/20 0.39
▸ TRPC5 Q9UL62 1/20 0.39
▸ GAA P10253 1/20 0.38
▸ DRD4 P21917 2/20 0.38
▸ RXFP1 Q9HBX9 1/20 0.38
▸ DRD2 P14416 1/20 0.38
▸ DRD3 P35462 1/20 0.38
▸ SMO Q99835 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11943320 0.91 ALDH1A1 (0.42) ALDH1A1KDM4EPOLBHPGDLMNA
SCHEMBL11943407 0.89 ALDH1A1 (0.42) ALDH1A1KDM4EPOLBHPGDLMNA
SCHEMBL14080954 0.85 ALDH1A1 (0.51) MAPK14ALDH1A1POLBLMNAMAPT
SCHEMBL11943422 0.85 MAPK14 (0.45) MAPK14ALDH1A1KDM4EPOLBHPGD
SCHEMBL11943340 0.85 ALDH1A1 (0.42) ALDH1A1KDM4EPOLBHPGDLMNA
SCHEMBL14081679 0.85 NPBWR1 (0.43) ALDH1A1KDM4EPOLBHPGDLMNA
SCHEMBL14082776 0.85 MAPK14 (0.44) MAPK14ALDH1A1POLBLMNAMAPT
SCHEMBL11943451 0.84 NPC1 (0.43) ALDH1A1KDM4EPOLBHPGDLMNA
SCHEMBL11943447 0.84 NPC1 (0.40) ALDH1A1KDM4EPOLBHPGDLMNA
SCHEMBL11943401 0.84 ALDH1A1 (0.47) MAPK14ALDH1A1KDM4EPOLBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20100158992-A1 PIPERAZINE-SUBSTITUTED PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS SCHERING CORPORATION (US) 2010-06-24 — — US disclosed
US-20100158992-A1 PIPERAZINE-SUBSTITUTED PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS SCHERING CORPORATION (US) 2010-06-24 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
WO-2008115385-A2 PIPERAZINE-SUBSTITUTED PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS SCHERING CORPORATION (US) 2008-09-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA MAPK14 2023/4885ALDH1A1 2437/4885KDM4E 1548/4885
US-20100158992-A1 PIPERAZINE-SUBSTITUTED PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS DPM1, GMPS, MAN2A1 MAPK14 936/4885ALDH1A1 2003/4885KDM4E 1706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback